Antibody to Extractable Nuclear Antigen Evaluation, Serum
Use
This test is useful for evaluating patients with clinical features suggestive of antinuclear antibody (ANA) associated connective tissue disease. It may also be indicated in patients who test negative for ANA but have features of Sjogren syndrome and idiopathic inflammatory myopathies. Antibodies to SS-A/Ro, SS-B/La, Smith (Sm), U1RNP (RNP68/A), Scl 70, and JO1 are associated with the presence of antinuclear antibodies and are useful in the evaluation of specific ANA-associated connective tissue diseases.
Special Instructions
Not provided.
Limitations
Negative results do not rule out the presence of connective tissue diseases. False positives may occur, and results must be interpreted in the correct clinical context. Gross hemolysis and lipemia in samples can lead to rejection of specimens.
FDA ApprovedNew York Approved
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
LOINC Codes
- 90228-8 - ENA Ab.IgG pnl Ser
- 33571-1 - ENA Jo1 IgG Ser-aCnc
- 29958-6 - ENA RNP IgG Ser IA-aCnc
- 47322-3 - ENA Scl70 IgG Ser IA-aCnc
- 18323-6 - ENA SM IgG Ser-aCnc
- 33610-7 - ENA SS-A IgG Ser-aCnc
- 33613-1 - ENA SS-B IgG Ser-aCnc
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.35 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis, Gross lipemia, Heat-Treated
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 21 days |
| Frozen | 21 days |